Almanack Investment Partners’s Amedisys AMED Stock Holding History

Almanack Investment Partners’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-31	Closed	-$3K	–	215
2022 Q3	$3K	Buy	+31	New	+$3.7K	﹤0.01%	645

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Almanack Investment Partners's AMED Position: Q4 2022 in Review

Almanack Investment Partners sold out of Amedisys (AMED) in Q4 2022, closing a stake of 31 shares — an estimated $3K sold.

Almanack Investment Partners first reported a position in AMED in Q3 2022 and held it in 1 quarter. The position peaked at $3K in Q3 2022. 277 funds tracked by Wall St. Rank hold AMED as of Q4 2022.

Almanack Investment Partners reported no remaining Amedisys position as of Q4 2022 after selling out during the quarter.
Almanack Investment Partners sold 31 Amedisys shares in Q4 2022, an estimated $3K.
Almanack Investment Partners first reported a position in Amedisys in Q3 2022 and held it in 1 quarter.
Almanack Investment Partners's Amedisys position peaked at $3K in Q3 2022.
277 funds tracked by Wall St. Rank held Amedisys as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.